GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Windlas Biotech Ltd (NSE:WINDLAS) » Definitions » EV-to-EBITDA

Windlas Biotech (NSE:WINDLAS) EV-to-EBITDA : 12.13 (As of Jun. 04, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Windlas Biotech EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Windlas Biotech's enterprise value is ₹11,116 Mil. Windlas Biotech's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was ₹916 Mil. Therefore, Windlas Biotech's EV-to-EBITDA for today is 12.13.

The historical rank and industry rank for Windlas Biotech's EV-to-EBITDA or its related term are showing as below:

NSE:WINDLAS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.56   Med: 8.03   Max: 22.66
Current: 12.13

During the past 6 years, the highest EV-to-EBITDA of Windlas Biotech was 22.66. The lowest was 4.56. And the median was 8.03.

NSE:WINDLAS's EV-to-EBITDA is ranked better than
57.38% of 711 companies
in the Drug Manufacturers industry
Industry Median: 14.26 vs NSE:WINDLAS: 12.13

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-04), Windlas Biotech's stock price is ₹631.35. Windlas Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ₹27.890. Therefore, Windlas Biotech's PE Ratio for today is 22.64.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Windlas Biotech EV-to-EBITDA Historical Data

The historical data trend for Windlas Biotech's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Windlas Biotech EV-to-EBITDA Chart

Windlas Biotech Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EV-to-EBITDA
Get a 7-Day Free Trial - - 4.84 4.92 9.42

Windlas Biotech Quarterly Data
Mar19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.92 8.49 7.53 10.61 9.42

Competitive Comparison of Windlas Biotech's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Windlas Biotech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Windlas Biotech's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Windlas Biotech's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Windlas Biotech's EV-to-EBITDA falls into.



Windlas Biotech EV-to-EBITDA Calculation

Windlas Biotech's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=11115.720/916.4
=12.13

Windlas Biotech's current Enterprise Value is ₹11,116 Mil.
Windlas Biotech's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹916 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Windlas Biotech  (NSE:WINDLAS) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Windlas Biotech's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=631.35/27.890
=22.64

Windlas Biotech's share price for today is ₹631.35.
Windlas Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹27.890.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Windlas Biotech EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Windlas Biotech's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Windlas Biotech (NSE:WINDLAS) Business Description

Traded in Other Exchanges
Address
Golf Course Extension Road, 705-706, Vatika Professional Point, Sector-66, Gurgaon, HR, IND, 122 001
Windlas Biotech Ltd is a pharmaceutical formulations contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.

Windlas Biotech (NSE:WINDLAS) Headlines

No Headlines